End-of-day quote
Taipei Exchange
03:30:00 15/05/2024 am IST
|
5-day change
|
1st Jan Change
|
99
TWD
|
-0.20%
|
|
-1.00%
|
+16.33%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
3,270
|
2,461
|
3,734
|
7,445
|
9,552
|
Enterprise Value (EV)
1 |
3,270
|
2,461
|
3,734
|
7,445
|
9,552
|
P/E ratio
|
39.4
x
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
5.23%
|
4.7%
|
5.05%
|
Capitalization / Revenue
|
-
|
0.96
x
|
1.18
x
|
1.89
x
|
2
x
|
EV / Revenue
|
-
|
0.96
x
|
1.18
x
|
1.89
x
|
2
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
16.2
x
|
53.2
x
|
-102
x
|
18
x
|
FCF Yield
|
-
|
6.19%
|
1.88%
|
-0.98%
|
5.57%
|
Price to Book
|
-
|
-
|
1.25
x
|
2.13
x
|
2.37
x
|
Nbr of stocks (in thousands)
|
88,390
|
78,112
|
78,112
|
87,481
|
96,487
|
Reference price
2 |
37.00
|
31.50
|
47.80
|
85.10
|
99.00
|
Announcement Date
|
29/03/21
|
29/03/22
|
28/03/23
|
21/03/24
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
-
|
2,571
|
3,169
|
3,930
|
4,773
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
161.4
|
341.6
|
543.3
|
720.5
|
Operating Margin
|
-
|
6.28%
|
10.78%
|
13.82%
|
15.1%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
101.8
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
|
0.9400
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
152.3
|
70.16
|
-72.65
|
532
|
FCF margin
|
-
|
5.93%
|
2.21%
|
-1.85%
|
11.15%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
2.500
|
4.000
|
5.000
|
Announcement Date
|
29/03/21
|
29/03/22
|
28/03/23
|
21/03/24
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
739.8
|
744
|
928.1
|
933.3
|
934.4
|
1,134
|
1,083
|
1,140
|
1,172
|
1,376
|
EBITDA
|
-
|
-
|
-
|
211.4
|
273.5
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
60.92
|
71.54
|
101.8
|
114.6
|
171.2
|
155.8
|
141.5
|
162.5
|
195
|
221
|
Operating Margin
|
8.24%
|
9.62%
|
10.96%
|
12.28%
|
18.32%
|
13.73%
|
13.07%
|
14.25%
|
16.63%
|
16.06%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/05/22
|
15/08/22
|
15/05/23
|
14/08/23
|
14/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
152
|
70.2
|
-72.7
|
532
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
11.8%
|
13.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
6.39%
|
7.41%
|
Assets
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
38.30
|
39.90
|
41.80
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
190
|
287
|
506
|
400
|
Capex / Sales
|
-
|
7.38%
|
9.05%
|
12.89%
|
8.38%
|
Announcement Date
|
29/03/21
|
29/03/22
|
28/03/23
|
21/03/24
|
-
|
Average target price
126
TWD Spread / Average Target +27.27% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.33% | 30Cr | | +10.79% | 12TCr | | -5.42% | 1.12TCr | | +4.17% | 916.62Cr | | -21.65% | 471.19Cr | | +8.82% | 344.12Cr | | -4.61% | 287.97Cr | | -12.05% | 211.11Cr | | -7.83% | 209.29Cr | | -22.84% | 179.8Cr |
Medical Devices & Implants
|